Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity

• Published in: Journal of nanobiotechnology Vol. 23; no. 1; pp. 194 - 22
• Main Authors: Liu, Yanhong, Gong, Liming, Feng, Jing, Xiao, Congcong, Liu, Chenfei, Chen, Bohan, Chen, Liqing, Jin, Mingji, Guan, Youyan, Gao, Zhonggao, Huang, Wei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.03.2025; BioMed Central; BMC
• Subjects: Animals; Anti-tumor immunotherapy; Axitinib; Axitinib - chemistry; Axitinib - pharmacology; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Cancer; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - immunology; Cell Line, Tumor; Dosage and administration; Drug therapy; Drug therapy, Combination; Female; Humans; Immune checkpoint inhibition; Immune Checkpoint Inhibitors - pharmacology; Immune response; Immunosuppressive microenvironment; Immunotherapy; Kidney Neoplasms - drug therapy; Kidney Neoplasms - immunology; Liposomes - chemistry; Methods; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic - drug therapy; Oncology, Experimental; Renal cell carcinoma; RNA, Small Interfering - pharmacology; Tumor Microenvironment - drug effects; Tumors; Vascular normalization; China; Immune checkpoint inhibition; Anti-tumor immunotherapy; Vascular normalization; Renal cell carcinoma; Immunosuppressive microenvironment

Immune checkpoint inhibition (ICI) has become the mainstay of immunotherapy for the treatment of renal cell carcinoma (RCC). However, only a small portion of patients exhibit a positive response to PD-1/PD-L1 blockade therapy and the key reason is that RCC belongs to a vascular-rich tumor for promot...